Comparison of the Efficacy of Dakotinib and Gefitinib in First-line Treatment of EGFR Exon19/21 Mutant Advanced Non-small Cell Lung Cancer
Objective To compare the efficacy of dacotinib and gefitinib in first-line treatment of EGFR Exon19/21 mu-tant advanced non-small cell lung cancer.Methods Data of 108 patients with Epidermal Growth Factor Receptor(EGER)mu-tant advanced Non-Small Cell Lung Cancer(NSCLC)were collected and divided into 2 groups according to different treatment methods.There were 58 cases in dacotinib group and 50 cases in gefitinib group.The curative effect of the 2 groups was analyzed.Results There was no significant difference in baseline characteristics between the 2 groups(P＞0.05).There was no significant difference in short-term efficacy between the dacotinib group and gefitinib group(P＞0.05).Follow-up was completed until June 2023,and no cases of abscission were reported in both groups.The median PFS in dacotinib group was longer than that in gefitinib group(12.6 vs 8.5 months,x2=34.009,P＜0.001).The median OS was 23.1 months in the Dakotinib group and 16.3 months in the gefitinib group,with no significant difference between the 2groups(x2=2.123,P=0.158).There was no statistical signifi-cance in the occurrence of adverse reactions between the two groups(P＜0.05),but the incidence of grade Ⅰ and Ⅱ gastrointes-tinal reactions and the incidence of grade Ⅲ and Ⅳ acne was slightly higher.Conclusions The efficacy of Dakotinib and ge-fitinib in first-line treatment of EGFR Exon19/21 advanced non-small cell lung cancer is similar,but the PFS of the Dakotinib group is more superior,and gefitinib is slightly safer than Dakotinib.
万方数据
维普
